April 19, 2022
Nippon Boehringer Ingelheim said on April 18 that its Japan sales in 2021 surged 6.7% year on year to 20.8 billion yen (ethical drugs on an NHI price basis), driven by double-digit growth of three major products including the SGLT2...read more